Ergot derivatives for Parkinsonism

D. B. Calne; A. C. Williams; J. G. Nutt; A. Neophytides; T. Eisler; P. F. Teychenne

doi:10.5694/j.1326-5377.1978.tb77384.x

Ergot derivatives for Parkinsonism

D. B. Calne, A. C. Williams, J. G. Nutt, A. Neophytides, T. Eisler, P. F. Teychenne

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

The response of Parkinsonism to three ergot derivatives which modify dopaminergic transmission was studied. CF 25-397 behaved more as an antagonist than an agonist. Lergotrile was an agonist with therapeutic properties marred by prominent hepatotoxicity. Bromocriptine is an effective anti-Parkinsonian agent, particularly useful in patients with prominent dyskinesia or 'on-off' reactions to levodopa; in most patients optimal results have been obtained by combining from 40 to 90 mg of bromocriptine daily with approximately 60% of the previous maximal dose of levodopa. Unfortunately, only some 50% of patients tolerate long-term bromocriptine therapy, but all adverse reactions have been dose dependent and reversible.

Original language	English (US)
Pages (from-to)	25-26
Number of pages	2
Journal	Unknown Journal
Volume	2
Issue number	Suppl. 3
DOIs	https://doi.org/10.5694/j.1326-5377.1978.tb77384.x
State	Published - 1979
Externally published	Yes

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.5694/j.1326-5377.1978.tb77384.x

Cite this

@article{667994e4b7274d6daa75947abaeb9e44,

title = "Ergot derivatives for Parkinsonism",

abstract = "The response of Parkinsonism to three ergot derivatives which modify dopaminergic transmission was studied. CF 25-397 behaved more as an antagonist than an agonist. Lergotrile was an agonist with therapeutic properties marred by prominent hepatotoxicity. Bromocriptine is an effective anti-Parkinsonian agent, particularly useful in patients with prominent dyskinesia or 'on-off' reactions to levodopa; in most patients optimal results have been obtained by combining from 40 to 90 mg of bromocriptine daily with approximately 60% of the previous maximal dose of levodopa. Unfortunately, only some 50% of patients tolerate long-term bromocriptine therapy, but all adverse reactions have been dose dependent and reversible.",

author = "Calne, {D. B.} and Williams, {A. C.} and Nutt, {J. G.} and A. Neophytides and T. Eisler and Teychenne, {P. F.}",

year = "1979",

doi = "10.5694/j.1326-5377.1978.tb77384.x",

language = "English (US)",

volume = "2",

pages = "25--26",

journal = "Unknown Journal",

issn = "0973-3698",

publisher = "Elsevier (Singapore) Pte Ltd",

number = "Suppl. 3",

}

TY - JOUR

T1 - Ergot derivatives for Parkinsonism

AU - Calne, D. B.

AU - Williams, A. C.

AU - Nutt, J. G.

AU - Neophytides, A.

AU - Eisler, T.

AU - Teychenne, P. F.

PY - 1979

Y1 - 1979

N2 - The response of Parkinsonism to three ergot derivatives which modify dopaminergic transmission was studied. CF 25-397 behaved more as an antagonist than an agonist. Lergotrile was an agonist with therapeutic properties marred by prominent hepatotoxicity. Bromocriptine is an effective anti-Parkinsonian agent, particularly useful in patients with prominent dyskinesia or 'on-off' reactions to levodopa; in most patients optimal results have been obtained by combining from 40 to 90 mg of bromocriptine daily with approximately 60% of the previous maximal dose of levodopa. Unfortunately, only some 50% of patients tolerate long-term bromocriptine therapy, but all adverse reactions have been dose dependent and reversible.

AB - The response of Parkinsonism to three ergot derivatives which modify dopaminergic transmission was studied. CF 25-397 behaved more as an antagonist than an agonist. Lergotrile was an agonist with therapeutic properties marred by prominent hepatotoxicity. Bromocriptine is an effective anti-Parkinsonian agent, particularly useful in patients with prominent dyskinesia or 'on-off' reactions to levodopa; in most patients optimal results have been obtained by combining from 40 to 90 mg of bromocriptine daily with approximately 60% of the previous maximal dose of levodopa. Unfortunately, only some 50% of patients tolerate long-term bromocriptine therapy, but all adverse reactions have been dose dependent and reversible.

UR - http://www.scopus.com/inward/record.url?scp=0018777641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018777641&partnerID=8YFLogxK

U2 - 10.5694/j.1326-5377.1978.tb77384.x

DO - 10.5694/j.1326-5377.1978.tb77384.x

M3 - Article

C2 - 34083

AN - SCOPUS:0018777641

SN - 0973-3698

VL - 2

SP - 25

EP - 26

JO - Unknown Journal

JF - Unknown Journal

IS - Suppl. 3

ER -

Ergot derivatives for Parkinsonism

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this